个人简述:

张建业，男，1978年出生，副教授，硕士研究生导师，广东省千百十第七批校级培养对象，中国抗癌协会抗癌药物专业委员会委员，中国药理学会肿瘤药理专业委员会委员。从事中药、天然药物的抗肿瘤研究，把化学成分研究与活性研究相结合。以肿瘤的靶点（包括耐药蛋白、干细胞干性分子、生长通路蛋白等）为研究对象，研究开发新型的抗肿瘤药物。主持过多项省市级项目，已发表多篇SCI文章，授权专利一项（一种POOLFQ-PCR联合检测肿瘤耐药基因的方法及其试剂盒，公开号102121048A），申请专利一项（专利申请号：201310345808.9）。2013年9月应邀在美国NIH举办的“10thAnnualNorthAmericanABCMeeting”上报告了中药千金子的活性成分对MDR细胞K562/ADR的逆转作用。

科研工作:

工作经历
    2008/07?至今，广州医科大学，药学院，副教授    2012/02?2014/01，香港浸会大学，中医药学院，访问学者     2003/08?2005/06，北京银建药业有限公司，新药研发项目经理
 发表文章：
 1.ZhangJY,LinMT,YiT,TangYN,FanLL,HeXC,ZhaoZZ,ChenHB.ApoptosissensitizationbyEuphorbiafactorL1inABCB1-mediatedmultidrugresistantK562/ADRcells.Molecules.2013,18(10):12793-808.(第一作者)2.ZhangJY,YiT,LiuJ,ZhaoZZ,ChenHB.QuercetininducesapoptosisviathemitochondrialpathwayinKBandKBv200cells.JAgricFoodChem.2013,61(9):2188-95.(第一作者)3.ZhangJY,LiangYJ,ChenHB,ZhengLS,MiYJ,WangF,ZhaoXQ,WangXK,ZhangH,FuLW.StructureidentificationofEuphorbiafactorL3anditsinductionofapoptosisthroughthemitochondrialpathway.Molecules.2011,16(4):3222-31.(第一作者，并列通讯作者)4.ZhangJY,MiYJ,ChenSP,WangF,LiangYJ,ZhengLS,ShiCJ,TaoLY,ChenLM,ChenHB,FuLW.EuphorbiafactorL1reversesABCB1-mediatedmultidrugresistanceinvolvinginteractionwithABCB1independentofABCB1downregualtion.JCellBiochem.2011,112(4):1076-83.(第一作者)5.ZhangJY,TaoLY,LiangYJ,ChenLM,MiYJ,ZhengLS,WangF,SheZG,LinYC,ToKK,FuLW.Anthracenedionederivativesasanticanceragentsisolatedfromsecondarymetabolitesofthemangroveendophyticfungi.MarDrugs.2010,8(4):1469-81.(第一作者)6.ZhangJY,TaoLY,LiangYJ,YanYY,DaiCL,XiaXK,SheZG,LinYC,FuLW.SecalonicacidDinducedleukemiacellapoptosisandcellcyclearrestofG1withinvolvementofGSK-3beta/beta-catenin/c-Mycpathway.CellCycle.2009,8(15):2444-50.(第一作者)7.ZhangJY,FuLW.Advanceofseveraltypesofimportantmarineantitumordrugs.YaoXueXueBao.2008,43(5):435-42.(第一作者，Review)8.ZhangJY,WuHY,XiaXK,LiangYJ,YanYY,SheZG,LinYC,FuLW.Anthracenedionederivative1403P-3inducesapoptosisinKBandKBv200cellsviareactiveoxygenspecies-independentmitochondrialpathwayanddeathreceptorpathway.CancerBiolTher.2007,6(9):1413-21.(第一作者)9.TaoLY,LiJY,ZhangJY.Brazilein,acompoundisolatedfromCaesalpiniasappanLinn.,inducedgrowthinhibitioninbreastcancercellsviainvolvementofGSK-3β/β-Catenin/cyclinD1pathway.ChemBiolInteract.2013,206(1):1-5.10.YiT,TangYN,ZhangJY,ZhaoZZ,YangZJ,ChenHB.Characterizationanddeterminationofsixflavonoidsintheethnomedicine"Dragon'sBlood"byUPLC-PAD-MS.ChemCentJ.2012,6(1):116.11.XiaX,ZhangJ,ZhangY,WeiF,LiuX,JiaA,LiuC,LiW,SheZ,LinY.PimaranediterpenesfromthefungusEpicoccumsp.HS-1associatedwithApostichopusjaponicus.BioorgMedChemLett.2012,22(8):3017-9.12.YanYY,ZhengLS,ZhangX,ChenLK,SinghS,WangF,ZhangJY,LiangYJ,DaiCL,GuLQ,ZengMS,TaleleTT,ChenZS,FuLW.BlockadeofHer2/neubindingtoHsp90byemodinazidemethylanthraquinonederivativeinducesproteasomaldegradationofHer2/neu.MolPharm.2011,8(5):1687-97.13.TaoLY,LJYandZhangJY.BrazileinovercameABCB1-mediatedmultidrugresistanceinhumanleukaemiaK562/AO2cells.AfrJPharmPharmaco.2011,5(16):1937-1944.14.WangXH,WangXK,LiangYJ,ShiZ,ZhangJY,ChenLM,FuLW.Acell-basedscreenforanticanceractivityof13pyrazolonederivatives.ChinJCancer.2010,29(12):980-7.15.TaoLY,ZhangJY,LiangYJ,ChenLM,ZhenLS,WangF,MiYJ,SheZG,ToKK,LinYC,FuLW.Anticancereffectandstructure-activityanalysisofmarineproductsisolatedfrommetabolitesofmangrovefungiintheSouthChinaSea.MarDrugs.2010,8(4):1094-105.16.LiangYJ,ZhangX,DaiCL,ZhangJY,YanYY,ZengMS,ChenLM,FuLW.BullatacintriggeredABCB1-overexpressingcellapoptosisviathemitochondrial-dependentpathway.JBiomedBiotechnol.20092009:867123.17.DengWJ,ZengZL,LiangYJ,DaiCL,ZhangJY,FuLW.DetectingdoxorubicinconcentrationinKBv200andKBcellxenograftsinnudemicebyhigh-performanceliquidchromatography.AiZheng.2008,27(4):364-8. 

教育背景:

2005/09?2008/06，中山大学，肿瘤防治中心，博士    2000/09?2003/06，北京大学，药学院，硕士    1996/09?2000/06，北京大学，药学院，学士研究